Optical News

MANHASSET, N.Y.--(BUSINESS WIRE)--Patients with metastatic uveal melanoma (UM), an aggressive eye cancer, often face a survival rate of less than two years once the disease spreads. While established treatment options are limited, to help patients living with this disease, Northwell Health’s Feinstein Institutes for Medical Research has announced findings from a Phase 1 clinical trial for DYP688, a first-in-class drug designed to treat metastatic UM. Published in Nature Medicine, the findings r...

INCHEON, Korea--(BUSINESS WIRE)--Samsung Epis Holdings announced its financial results for the second quarter and first half of fiscal year 2026....

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc., “iVeena” a clinical-stage ophthalmic pharmaceutical company developing innovative therapies for eye diseases, today announced a successful End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration (FDA) for IVMED-85, an investigational, non-atropine eye drop being developed for the treatment of pediatric myopia. The meeting followed the recently announced successful completion of iVeena's Phase 1 clinical study evalu...

ALAMEDA, Calif. & PARIS--(BUSINESS WIRE)--Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced the European commercial launch of PRIMA, the first and only treatment shown in clinical trials to restore functional central vision to patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD), a leading cause of blindness. PRIMA has received a CE (Conformité Européenne) mark under the European Union Medical Device Regulat...

TOKYO & COLUMBUS, Ohio--(BUSINESS WIRE)--Restore Vision, Inc. (“Restore Vision”), a clinical-stage biotechnology company advancing gene therapies for retinal disorders, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to support RV-001, Restore Vision’s investigational GPCR-based optogenetic AAV gene therapy for patients with retinitis pigmentosa. Through this collabor...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Radiology Partners, Inc. (RP), through RP Clinical Services and its affiliated practices, today announced two leadership appointments, effective July 20. Matt Peterson has been named President of RP Clinical Services, reporting to Rich Whitney, Chairman and Chief Executive Officer of RP. Krishna Nallamshetty, MD, will become full-time Chief Operating Officer of RP Clinical Services after serving as Interim COO since December, and will also serve as Interim Chi...

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics' K8 slowed GA lesion growth 54% and showed a 4.0-letter vision advantage at six months in Phase 2. Phase 3 planned....

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc., (“iVeena”) a clinical-stage ophthalmic biopharmaceutical company, today announced the successful completion of its Phase 1 clinical trial evaluating the safety of IVMED-85, an investigational, preservative-free ophthalmic solution being developed for the treatment of pediatric myopia. iVeena has completed the first-in-human, randomized, double-masked, vehicle-controlled Phase 1 study, which demonstrated a favorable safety profile a...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second quarter ended July 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement, which it expects to issue on August 12, 2026.Net sales for the second quarter of 2026 are expected to be in excess of...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated optic portfolio to suit a wide range of patients,” said Wayne Caulder, vice president and general manager, North America Surgi...